| Filed On | Filing |
|---|---|
| 21 Oct 2026 |
8-K: Other Events
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company |
| 21 Oct 2026 |
8-K: Results of Operations and Financial Condition
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance |
| 20 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants |
| 16 Jul 2026 |
8-K: Results of Operations and Financial Condition
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance |
| 27 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective April 24, 2026 |
| 17 Apr 2026 |
8-K: Other Events
This notice (the “Notice”) advises you of the proposed settlement (the “Settlement”) of derivative claims brought against certain current and former directors and officers (“Individual Defendants”) of Abbott Laboratories (“Abbott” or the... |
| 16 Apr 2026 |
8-K: Results of Operations and Financial Condition
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences |
| 23 Mar 2026 |
8-K: Other Events
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments |
| 09 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
The undersigned, Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer of Abbott Laboratories (“Abbott” or the “Company”), and James R. Wenner, Vice President, Treasurer of the Company, hereby certify, pursuan... |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
Abbott Laboratories, an Illinois corporation (the “Company”), proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement, dated March 5, 2015 (the “Underwriting Agreement”), between the Company and the ... |
| 20 Feb 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, December 12, 2025 as amended and restated, effective April 24, 2026 |
| 22 Jan 2026 |
8-K: Results of Operations and Financial Condition
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook |
| 12 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year
Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective December 12, 2025 |
| 21 Nov 2025 |
8-K: Temporary Suspension of Trading Under Employee Benefit Plans
This notice explains certain restrictions on your investments in securities of Abbott Laboratories (“Abbott”) during an upcoming retirement plan blackout period. As a director or executive officer of Abbott, you are subject to restrictio... |
| 20 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments |
| 15 Oct 2025 |
8-K: Results of Operations and Financial Condition
Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance |
| 17 Jul 2025 |
8-K: Results of Operations and Financial Condition
–Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 |
| 01 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 28 Apr 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Abbott held its Annual Meeting of Shareholders on April 25, 2025. The following is a summary of the matters voted on at that meeting. |
| 16 Apr 2025 |
8-K: Results of Operations and Financial Condition
Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance |
Loading...